Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.70 |
| ▸ | MEN1 | O00255 | 12/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | RBP4 | P02753 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5849523 | 0.84 | P2RY12 (0.74) | P2RY12MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL7064496 | 0.83 | ALDH1A1 (0.52) | P2RY12MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5851617 | 0.83 | P2RY12 (0.82) | P2RY12MEN1KMT2AALDH1A1 | |
| SCHEMBL5851381 | 0.82 | P2RY12 (1.00) | P2RY12MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5851612 | 0.82 | P2RY12 (0.71) | P2RY12MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5849809 | 0.81 | P2RY12 (0.73) | P2RY12MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5849588 | 0.80 | P2RY12 (0.68) | P2RY12MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5849512 | 0.80 | P2RY12 (0.85) | P2RY12MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5849667 | 0.80 | KDM4E (0.71) | P2RY12MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL5849530 | 0.79 | KIT (0.52) | P2RY12MEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |